Encision Reports First Quarter Fiscal Year 2026 Results

NYSE - LSE

BCC	-4.57%	79	$
CMSC	-0.04%	22.82	$
BCE	-1.03%	23.26	$
NGG	-1.71%	85.98	$
CMSD	-0.61%	23.06	$
GSK	-5.97%	51.4	$
RIO	-2.07%	96.49	$
RBGPF	0.44%	63.75	$
JRI	-0.55%	12.74	$
BTI	-1.78%	57.45	$
RYCEF	-2.68%	14.9	$
BP	0.96%	46.8	$
VOD	-0.98%	15.34	$
RELX	-0.59%	35.8	$
AZN	-0.8%	185.2	$

Encision Reports First Quarter Fiscal Year 2026 Results

BOULEVARD 15.08.2025

BOULDER, CO / ACCESS Newswire / August 15, 2025 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2025 first quarter that ended June 30, 2025.

Text size:

The Company posted quarterly product net revenue of $1.49 million and service net revenue of $110 thousand, or total net revenue of $1.6 million for a quarterly net loss of $41 thousand, or $0.00 per diluted share. These results compare to product net revenue of $1.59 million and service net revenue of $38 thousand, or total net revenue of $1.63 million for a quarterly net income of $22 thousand, or $(0.00) per diluted share, in the year-ago quarter. Gross margin on product net revenue was 55% in the fiscal 2026 first quarter and 58% in the fiscal 2025 first quarter.

Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Brandon Shepard , Encision Inc., 303-444-2600, [email protected]

Encision Inc.
Condensed Balance Sheets

	June 30, 2025		March 31, 2025
	Unaudited		Audited
ASSETS
Current assets:
Cash	$	47,918	$	257,433
Accounts receivable	749,426	786,471
Inventories	1,534,887	1,483,182
Prepaid expenses	118,308	85,679
Total current assets	2,450,539	2,612,765
Equipment:
Furniture, fixtures, and equipment, at cost	2,591,981	2,585,446
Accumulated depreciation	(2,358,134	)	(2,340,689	)
Equipment, net	233,847	244,757
Right of use asset, net	1,199,806	568,395
Patents, net	166,708	171,890
Other assets	80,655	72,892
TOTAL ASSETS	4,131,555	3,670,699
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	328,123	$	346,900
Line of credit	320,440	395,964
Secured notes	39,802	44,128
Accrued compensation	208,850	180,850
Deferred Revenue	2,574	17,401
Other accrued liabilities	129,615	160,274
Accrued lease liability	248,469	430,398
Total current liabilities	1,277,873	1,575,915
Long-term liability:
Secured notes	169,997	177,470
Accrued lease liability	1,061,597	266,212
Total liabilities	2,509,467	2,019,597
Commitments and contingencies (Note 4)
Shareholders' equity:
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding	-	-
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 11,879,645 and 11,879,645 issued and outstanding at June 30, 2025, and March 31, 2025, respectively	24,428,466	24,416,347
Accumulated (deficit)	(22,806,378	)	(22,765,245	)
Total shareholders' equity	1,622,088	1,651,102
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	4,131,555	$	3,670,699

Encision Inc.
Condensed Statements of Operations
(Unaudited)

	Three Months Ended
	June 30, 2025		June 30, 2024
NET REVENUE:
Product	$	1,492,832	$	1,591,960
Service	109,896	38,971
Total revenue	1,602,728	1,630,931

COST OF REVENUE:
Product	666,811	667,635
Service	57,458	20,633
Total cost of revenue	724,269	688,268
GROSS PROFIT	878,459	942,663

OPERATING EXPENSES:
Sales and marketing	404,601	423,237
General and administrative	328,198	351,903
Research and development	165,440	139,180
Total operating expenses	898,239	914,320
OPERATING (LOSS) INCOME	(19,780	)	28,343
Interest expense, net	(18,009	)	(6,369	)
Other (expense) income, net	(3,344	)	67
Interest expense and other (expense), income, net	(21,353	)	(6,302	)
(LOSS) INCOME BEFORE PROVISION FOR INCOME TAXES	(41,133	)	22,041
Provision for income taxes	-	-
NET (LOSS) INCOME	$	(41,133	)	$	22,041

Net (loss) income per share-basic and diluted	$	(0.00	)	$	(0.00	)
Weighted average shares-basic	11,879,645	11,879,145
Weighted average shares-diluted	11,879,645	11,906,918

Encision Inc.
Condensed Statements of Cash Flows
(Unaudited)

Three Months Ended	June 30, 2025		June 30, 2024
Cash flows (used in) operating activities:
Net (loss) income	$	(41,133	)	$	22,041
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	22,777	19,322
Stock-based compensation expense	12,119	12,374
Provision for inventory obsolescence, net change	3,982	1,090
Change in operating assets and liabilities:
Right of use asset, net	(17,955	)	(3,456	)
Accounts receivable	37,046	74,980
Inventories	(55,687	)	83,125
Prepaid expenses and other assets	(40,393	)	(21,587	)
Accounts payable	(33,605	)	(76,123	)
Accrued compensation and other accrued liabilities	(2,659	)	5,762
Net cash provided by (used in) provided by operating activities	(115,508	)	117,528
Cash flows (used in) investing activities:
Acquisition of property and equipment	(6,535	)	(14,144	)
Patent costs	(150	)	(5,397	)
Net cash (used in) investing activities	(6,685	)	(19,541	)
Cash flows from financing activities:
(Payments) to borrowing from line of credit	(75,524	)	142,736
(Payments) from options exercised	-	(1,449	)
(Paydown) Secured notes	(11,798	)	(11,339	)
Net cash (used in) provided by financing activities	(87,322	)	129,948

Net (decrease) increase in cash	(209,515	)	227,935
Cash, beginning of fiscal year	257,433	42,509
Cash, end of fiscal quarter	47,918	270,444

Supplemental disclosures of cash flow information:
Cash paid during the period for interest	$	18,009	$	6,369

SOURCE: Encision, Inc.

View the original press release on ACCESS Newswire

H.Romero--AT

Arizona Tribune - Encision Reports First Quarter Fiscal Year 2026 Results

Encision Reports First Quarter Fiscal Year 2026 Results

Featured

Cambodia deports more than 600 Thais linked to cyberscams: minister

Afghan women footballers celebrate 'historic moment'

Afghan women footballers celebrate 'historical moment'

Teen with 30 tortoises under clothes nabbed at Thai airport